scPharmaceuticals Q3 2022 Earnings Report
Key Takeaways
scPharmaceuticals reported a net loss of $10.2 million for the third quarter of 2022 and ended the quarter with $45.4 million in cash, cash equivalents, restricted cash and investments. The FDA approved FUROSCIX in October 2022, and the company entered into a secured debt financing agreement for up to $100 million with Oaktree Capital.
Announced FDA marketing approval of FUROSCIX.
Entered into a secured debt financing agreement for up to $100 million with funds managed by Oaktree Capital.
Advanced commercial readiness activities in support of upcoming FUROSCIX commercial launch planned in Q1 2023.
Ended the third quarter with cash, cash equivalents, restricted cash and investments of $45.4 million.
scPharmaceuticals
scPharmaceuticals
Forward Guidance
The Company has adjusted its 2022 net loss to $38 to $41 million, a decrease over prior guidance of $43 to $48 million.